Perrigo Company Faces Class Action Lawsuit Over Investor Misleading Claims
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Businesswire
- Lawsuit Background: Rosen Law Firm reminds investors of a class action lawsuit against Perrigo Company for misleading investors regarding its business operations from February 27, 2023, to November 4, 2025.
- Investor Losses: The lawsuit alleges that Perrigo's acquisition of Nestlé's infant formula business suffered from significant underinvestment, leading to overstated financial results and subsequent investor losses.
- Operational Deficiencies: Allegations highlight significant manufacturing deficiencies in Perrigo's infant formula business, necessitating substantial capital and operational expenditures beyond the company's publicly stated cost estimates for remediation.
- Legal Proceedings: Investors wishing to serve as lead plaintiffs must file motions with the court by January 16, 2026, with all representation on a contingency fee basis, meaning shareholders incur no fees or expenses.
Analyst Views on PRGO
Wall Street analysts forecast PRGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRGO is 27.50 USD with a low forecast of 23.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 15.170
Low
23.00
Averages
27.50
High
32.00
Current: 15.170
Low
23.00
Averages
27.50
High
32.00
About PRGO
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
